Biohaven Ltd.

About Biohaven Ltd.

Biohaven is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology, and oncology. Their mission is driven by urgency and intention to address diseases with significant unmet medical needs, focusing on patient-first culture and scientific innovation.

Products & Services

Nurtec® ODT (rimegepant):A treatment for migraine, representing a groundbreaking legacy in transforming migraine therapy.

Zavzpret® (zavegepant):Another innovative treatment for migraine, part of Biohaven's successful portfolio in neuroscience.

BHV-1300:A potential first-in-class degrader achieving over 80% sustained reductions in total IgG, currently under development.

BHV-1400:A potential first-in-class treatment for IgA Nephropathy (IgAN), achieving significant reductions in Gd-IgA1.

TYK2/JAK1 Inhibitor:A novel brain-penetrant inhibitor targeting neuroinflammation, in Phase 2/3 trials for early Parkinson's disease.

Trop2 and FGFR3 Antibody Drug Conjugates (ADCs):Innovative oncology treatments incorporating novel TopoIx payload, with potential to treat a wide variety of tumors.

Nurtec ODT (rimegepant)

Zavzpret (zavegepant)

Specialties

Neuroscience Immunology Oncology Clinical Trials Drug Development Platforms Migraine Treatment Neuroinflammation Antibody Drug Conjugates (ADCs) neuroscience immunology oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 600000000 MR: - FA: up to $600 million FAN: 600000000	D: 2025-04-28 FD: 2025-04-28	1 investors

Debt Latest

2025-04-28

$600.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Vlad Coric

CHAIRMAN & CHIEF EXECUTIVE OFFICER

M

Matthew Buten

CHIEF FINANCIAL OFFICER

C

Cliff Bechtold

PRESIDENT & GENERAL MANAGER, BIOHAVEN IRELAND, CHIEF COMPLIANCE OFFICER

K

Kimberly Gentile

SENIOR VICE PRESIDENT, CLINICAL OPERATIONS

I

Irfan Qureshi

CHIEF MEDICAL OFFICER

B

Bruce D. Car

CHIEF SCIENTIFIC OFFICER

View 206 more team members with Pro

Unlock Full Team Directory

Recent News

Biohaven Ltd. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised